![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 51, 53725-53735, December 17, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B Activation via a Novel Pathway in BV-2 Microglia*






||
From the
Department of Neurology and Neuroscience, Weill Medical College of Cornell University and Burke Medical Research Institute, White Plains, New York 10605 and ¶Department of Rehabilitation Medicine, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea
Transglutaminase 2 (TGase 2) expression is increased in inflammatory diseases. We demonstrated previously that inhibitors of TGase 2 reduce nitric oxide (NO) generation in a lipopolysaccharide (LPS)-treated microglial cell line. However, the precise mechanism by which TGase 2 promotes inflammation remains unclear. We found that TGase 2 activates the transcriptional activator nuclear factor (NF)-
B and thereby enhances LPS-induced expression of inducible nitric-oxide synthase. TGase 2 activates NF-
B via a novel pathway. Rather than stimulating phosphorylation and degradation of the inhibitory subunit
of NF-
B (I-
B
), TGase2 induces its polymerization. This polymerization results in dissociation of NF-
B and its translocation to the nucleus, where it is capable of up-regulating a host of inflammatory genes, including inducible nitric-oxide synthase and tumor necrosis factor
(TNF-
). Indeed, TGase inhibitors prevent depletion of monomeric I-
B
in the cytosol of cells overexpressing TGase 2. In an LPS-induced rat brain injury model, TGase inhibitors significantly reduced TNF-
synthesis. The findings are consistent with a model in which LPS-induced NF-
B activation is the result of phosphorylation of I-
B
by I-
B kinase as well as I-
B
polymerization by TGase 2. Safe and stable TGase2 inhibitors may be effective agents in diseases associated with inflammation.
Received for publication, July 7, 2004 , and in revised form, October 4, 2004.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this work.
|| To whom correspondence should be addressed. Tel.: 914-597-2500, ext. 3041; Fax: 914-597-2757; E-mail: tgase{at}hanmail.net.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. Y. Hwang, L. S. Mangala, J. Y. Fok, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, D. J. Fiterman, P. E. Vivas-Mejia, M. T. Deavers, et al. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma Cancer Res., July 15, 2008; 68(14): 5849 - 5858. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Falasca, M. G. Farrace, A. Rinaldi, L. Tuosto, G. Melino, and M. Piacentini Transglutaminase Type II Is Involved in the Pathogenesis of Endotoxic Shock J. Immunol., February 15, 2008; 180(4): 2616 - 2624. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sethi, B. Sung, and B. B. Aggarwal Nuclear Factor-{kappa}B Activation: From Bench to Bedside Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-S. Lai, Y. Liu, W. Li, and C. S. Greenberg Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells FASEB J, December 1, 2007; 21(14): 4131 - 4143. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zer, G. Sachs, and J. M. Shin Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-{alpha} signaling Physiol Genomics, October 19, 2007; 31(2): 343 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-S. Park, J.-M. Kim, D.-S. Kim, I.-H. Kim, and S.-Y. Kim Transglutaminase 2 Mediates Polymer Formation of I-{kappa}B{alpha} through C-terminal Glutamine Cluster J. Biol. Chem., November 17, 2006; 281(46): 34965 - 34972. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-S. Kim, S.-S. Park, B.-H. Nam, I.-H. Kim, and S.-Y. Kim Reversal of Drug Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and Nuclear Factor-{kappa}B Inactivation. Cancer Res., November 15, 2006; 66(22): 10936 - 10943. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Mann, A. Verma, G. Sethi, B. Manavathi, H. Wang, J. Y. Fok, A. B. Kunnumakkara, R. Kumar, B. B. Aggarwal, and K. Mehta Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway. Cancer Res., September 1, 2006; 66(17): 8788 - 8795. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Tong, R. M. Corrales, Z. Chen, A. L. Villarreal, C. S. De Paiva, R. Beuerman, D.-Q. Li, and S. C. Pflugfelder Expression and Regulation of Cornified Envelope Proteins in Human Corneal Epithelium Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1938 - 1946. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Liu and A. B. Malik NF-{kappa}B activation as a pathological mechanism of septic shock and inflammation Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L622 - L645. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mishra, A. Saleh, P. S. Espino, J. R. Davie, and L. J. Murphy Phosphorylation of Histones by Tissue Transglutaminase J. Biol. Chem., March 3, 2006; 281(9): 5532 - 5538. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |